Skip to Main Content

Paper Details

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
Lancet Oncol
103
2017
advanced prostate cancer, aspartate, aspartate aminotransferase, cancer, docetaxel, metastatic castration-resistant prostate cancer, participants, patients, prednisolone, prednisone
Author NameAffiliation
Justin Guinney
Justin Guinney
Tao WangQuantitative Biomedical Research Center, University of Texas Southwestern Medical Center, USA Center for the Genetics of Host Defense
James Christopher Bare
Elias Chaibub Neto
Suleiman A KhanInstitute for Molecular Medicine Finland (FIMM), University of Helsinki
Peddinti GopalacharyuluInstitute for Molecular Medicine Finland (FIMM), University of Helsinki
Antti AirolaUniversity of Turku
Tapio PahikkalaUniversity of Turku
Thomas Yu
Brian M Bot
Thea Norman
Stephen H Friend
Gustavo StolovitzkyIBM T J Watson Research Center
Gustavo StolovitzkyIBM T J Watson Research Center
Howard I ScherSidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College
Oliver SartorTulane Cancer Center, Tulane University
Yang XieQuantitative Biomedical Research Center, University of Texas Southwestern Medical Center, USA The Simmons Comprehensive Cancer Center
Tero AittokallioUniversity of Turku, Finland Institute for Molecular Medicine Finland (FIMM), University of Helsinki
James C CostelloUniversity of Colorado, USA University of Colorado Comprehensive Cancer Center
  • 1 - 20

Datasets